trucode gene repair is advancing its novel triplex gene editing platform to potentially cure devastating genetic diseases, with initial focus on sickle cell disease and cystic fibrosis. the elegance of triplex gene editing lies in its ability to harness natural, high-fidelity dna repair mechanisms, and its independence from the requirement for exogenous nucleases and viral vectors.
Company profile
Ticker
VERA
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
812744449
VERA stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
27 Mar 24
10-K
2023 FY
Annual report
26 Mar 24
8-K
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
20 Mar 24
8-K
Other Events
30 Jan 24
424B5
Prospectus supplement for primary offering
30 Jan 24
S-3MEF
Registration of additional securities for an S-3
29 Jan 24
424B5
Prospectus supplement for primary offering
29 Jan 24
8-K
Results of Operations and Financial Condition
29 Jan 24
8-K
Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
25 Jan 24
8-K
Departure of Directors or Certain Officers
8 Jan 24
Latest ownership filings
SC 13D/A
Sofinnova Venture Partners X, L.P.
26 Mar 24
4
Maha Katabi
25 Mar 24
144
Notice of proposed sale of securities
21 Mar 24
SC 13D/A
Sofinnova Venture Partners X, L.P.
20 Feb 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
COMMODORE CAPITAL LP
14 Feb 24
SC 13G/A
COMMODORE CAPITAL LP
14 Feb 24
SC 13G/A
Ares Trading S.A.
14 Feb 24
SC 13G/A
Kynam Capital Management, LP
14 Feb 24
SC 13G
Woodline Partners LP
12 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 27.44 mm | 27.44 mm | 27.44 mm | 27.44 mm | 27.44 mm | 27.44 mm |
Cash burn (monthly) | 2.15 mm | 277.25 k | 7.25 mm | 9.05 mm | 7.66 mm | 7.35 mm |
Cash used (since last report) | 12.81 mm | 1.65 mm | 43.21 mm | 53.91 mm | 45.63 mm | 43.80 mm |
Cash remaining | 14.63 mm | 25.79 mm | -15.77 mm | -26.47 mm | -18.19 mm | -16.36 mm |
Runway (months of cash) | 6.8 | 93.0 | -2.2 | -2.9 | -2.4 | -2.2 |
Institutional ownership, Q2 2023
84.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 83 |
Opened positions | 23 |
Closed positions | 12 |
Increased positions | 31 |
Reduced positions | 19 |
13F shares | Current |
---|---|
Total value | 610.49 bn |
Total shares | 46.37 mm |
Total puts | 123.00 k |
Total calls | 172.70 k |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
FMR | 6.54 mm | $104.90 bn |
Commodore Capital | 5.45 mm | $87.47 bn |
Sofinnova Investments | 3.47 mm | $55.65 bn |
Sofinnova Venture Partners X | 3.47 mm | $24.17 mm |
Longitude Capital Partners IV | 3.43 mm | $23.91 mm |
Kynam Capital Management | 3.00 mm | $48.15 bn |
CG Carlyle Group Inc | 2.42 mm | $38.77 bn |
BLK Blackrock | 2.17 mm | $34.83 bn |
Orbimed Advisors | 1.76 mm | $28.20 bn |
Woodline Partners | 1.75 mm | $28.15 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Mar 24 | Maha Katabi | Class A Common Stock | Sell | Dispose S | Yes | No | 40.5 | 340,000 | 13.77 mm | 2,793,987 |
22 Mar 24 | Maha Katabi | Class A Common Stock | Sell | Dispose S | Yes | No | 40.51 | 413,450 | 16.75 mm | 3,133,987 |
21 Mar 24 | Maha Katabi | Class A Common Stock | Sell | Dispose S | Yes | No | 46.18 | 13,718 | 633.50 k | 3,547,437 |
21 Mar 24 | Maha Katabi | Class A Common Stock | Sell | Dispose S | Yes | No | 45.52 | 12,617 | 574.33 k | 3,561,155 |
21 Mar 24 | Maha Katabi | Class A Common Stock | Sell | Dispose S | Yes | No | 44 | 21,918 | 964.39 k | 3,573,772 |
21 Mar 24 | Maha Katabi | Class A Common Stock | Sell | Dispose S | Yes | No | 43 | 32,756 | 1.41 mm | 3,595,690 |
30 Jan 24 | Maha Katabi | Class A Common Stock | Buy | Acquire P | Yes | No | 31 | 161,290 | 5.00 mm | 3,628,446 |
16 Jan 24 | Sean Grant | Class A Common Stock | Grant | Acquire A | No | No | 0 | 26,250 | 0.00 | 78,683 |
16 Jan 24 | Sean Grant | Stock Option Class A Common Stock | Grant | Acquire A | No | No | 16.8 | 97,500 | 1.64 mm | 97,500 |
16 Jan 24 | Joseph R Young | Class A Common Stock | Grant | Acquire A | No | No | 0 | 21,875 | 0.00 | 57,054 |
News
Guggenheim Maintains Buy on Vera Therapeutics, Raises Price Target to $56
27 Mar 24
Wedbush Maintains Neutral on Vera Therapeutics, Raises Price Target to $34
21 Mar 24
Vera Therapeutics: Q4 Earnings Insights
20 Mar 24
$10M Bet On ArriVent BioPharma? Check Out These 4 Stocks Insiders Are Buying
2 Feb 24
(VERA) - Analyzing Vera Therapeutics's Short Interest
31 Jan 24
Press releases
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
20 Mar 24
Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference
28 Feb 24
Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock
29 Jan 24
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
29 Jan 24
Thinking about trading options or stock in TAL Education, Vera Therapeutics, MarineMax, General Motors, or Boyd Gaming?
25 Jan 24